Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tenax Therapeutics (TENX) Income from Continuing Operations (2016 - 2026)

Tenax Therapeutics' Income from Continuing Operations history spans 7 years, with the latest figure at 17029572.0 for Q4 2017.

  • On a quarterly basis, Income from Continuing Operations rose 74.78% to 17029572.0 in Q4 2017 year-over-year; TTM through Dec 2017 was 9205897.0, a 85.63% increase, with the full-year FY2025 number at 52566000.0, down 198.62% from a year prior.
  • Income from Continuing Operations hit 17029572.0 in Q4 2017 for Tenax Therapeutics, down from 1310420.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for TENX hit a ceiling of 4671235.0 in Q2 2016 and a floor of 67527869.0 in Q4 2016.
  • Historically, Income from Continuing Operations has averaged 7380198.92 across 4 years, with a median of 2413277.0 in 2013.
  • The widest YoY moves for Income from Continuing Operations: up 244.99% in 2016, down 547.62% in 2016.
  • Tracing TENX's Income from Continuing Operations over 4 years: stood at 1862494.0 in 2013, then crashed by 459.84% to 10427005.0 in 2015, then tumbled by 547.62% to 67527869.0 in 2016, then soared by 74.78% to 17029572.0 in 2017.
  • Business Quant data shows Income from Continuing Operations for TENX at 17029572.0 in Q4 2017, 1310420.0 in Q3 2017, and 3014369.0 in Q2 2017.